Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis
- PMID: 32049748
- PMCID: PMC7190228
- DOI: 10.1097/CM9.0000000000000691
Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis
Abstract
Background: Clinically amyopathic dermatomyositis (CADM) is a unique sub-type of idiopathic inflammatory myopathies with a high prevalence of interstitial lung disease (ILD). Poor prognosis of the patients was strongly associated with rapid progressive ILD. The aim of this study was to identify risk factors for prediction of different types of ILD in CADM.
Methods: In this study, data of 108 inpatients with CADM were collected, including 87 with ILD. The baseline clinical data and laboratory parameters, including myositis-specific and associated antibodies and tumor-associated antigens were analyzed to identify risk factors for acute or subacute interstitial pneumonitis (A/SIP) and chronic interstitial pneumonitis (CIP).
Results: In 87 patients with CADM-ILD, 39 (36.1%) were A/SIP, and 48 (44.4%) were CIP. There were 22 (20.4%) patients with asymptomatic ILD who were detected by routine high resolution computed tomography. Cytokeratin-19 fragment (CYFRA21-1) was significantly higher in CADM-ILD than that in CADM patients without ILD; carcinoembryonic antigen and neuron-specific enolase were significantly elevated in A/SIP than that in CIP. Patients with A/SIP had a higher positive rate of anti-melanoma differentiation-associated gene 5 (MDA5), while patients with CIP had a higher positive rate of anti PL-12 and anti-Ro-52. Logistic regression analysis indicated that elevation of CYFRA21-1 was a risk factor for ILD, higher titer of anti-MDA5 indicated increased likelihood for A/SIP, and higher titer of anti-Ro-52 was also clearly associated with CIP.
Conclusions: This study indicated that the prevalence of ILD was high in CADM. Asymptomatic ILD has been previously underestimated. Anti-MDA5 was a risk factor for the presence of A/SIP, and CYFRA21-1 was a risk factor for ILD.
Conflict of interest statement
None.
Similar articles
-
Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.Front Immunol. 2023 Nov 27;14:1237209. doi: 10.3389/fimmu.2023.1237209. eCollection 2023. Front Immunol. 2023. PMID: 38098481 Free PMC article.
-
Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.Rheumatology (Oxford). 2021 Aug 2;60(8):3913-3922. doi: 10.1093/rheumatology/keaa843. Rheumatology (Oxford). 2021. PMID: 33501503
-
Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.Rheumatology (Oxford). 2019 Dec 1;58(12):2143-2152. doi: 10.1093/rheumatology/kez185. Rheumatology (Oxford). 2019. PMID: 31143953
-
Management of Myositis-Associated Interstitial Lung Disease.Medicina (Kaunas). 2021 Apr 3;57(4):347. doi: 10.3390/medicina57040347. Medicina (Kaunas). 2021. PMID: 33916864 Free PMC article. Review.
-
Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.Rheumatol Int. 2018 Jul;38(7):1293-1296. doi: 10.1007/s00296-018-3991-7. Epub 2018 Feb 7. Rheumatol Int. 2018. PMID: 29417209 Free PMC article. Review.
Cited by
-
Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.Front Immunol. 2023 Nov 27;14:1237209. doi: 10.3389/fimmu.2023.1237209. eCollection 2023. Front Immunol. 2023. PMID: 38098481 Free PMC article.
-
Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis.BMJ Open Respir Res. 2023 Nov 29;10(1):e002076. doi: 10.1136/bmjresp-2023-002076. BMJ Open Respir Res. 2023. PMID: 38030264 Free PMC article.
-
Treatment of refractory anti-melanoma differentiation-associated gene 5 anbibody-positive dermatomyositis complicated by rapidly progressing interstitial pulmonary disease: Two case reports.World J Clin Cases. 2023 Aug 6;11(22):5351-5357. doi: 10.12998/wjcc.v11.i22.5351. World J Clin Cases. 2023. PMID: 37621599 Free PMC article.
-
Predictors of progression in idiopathic inflammatory myopathies with interstitial lung disease.J Transl Int Med. 2022 Nov 15;11(1):46-56. doi: 10.2478/jtim-2022-0029. eCollection 2023 Mar. J Transl Int Med. 2022. PMID: 37533847 Free PMC article.
-
The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series.J Clin Med. 2023 May 11;12(10):3406. doi: 10.3390/jcm12103406. J Clin Med. 2023. PMID: 37240516 Free PMC article.
References
-
- Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46:626–636. doi: 10.1067/mjd.2002.120621. - PubMed
-
- Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597–613. doi: 10.1016/j.jaad.2005.10.041. - PubMed
-
- Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol 2016; 35:113–116. doi: 10.1007/s10067-015-3139-z. - PubMed
-
- Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep 2014; 16:465.doi: 10.1007/s11926-014-0465-0. - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
